More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early
Multi-Modal Candidate Meets Endpoint In Pancreatic Setting
Executive Summary
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
You may also be interested in...
Exelixis’s Cabometyx Two-For-Two In A Week As Neuroendocrine Tumor Study Hits Endpoint
The announcement of the CABINET study’s success follows by days positive results for CONTACT-02 in prostate cancer, though NETs represent a smaller commercial opportunity.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.